OR WAIT null SECS
The company expanded its topicals capacity with an investment in the Becomix RW30 model homogenizer.
Juniper Pharma Services announced on May 17, 2016 that it has invested in the Becomix RW30 model homogenizer, giving them the ability to supply products for Phase III studies. According to Juniper, the addition of the equipment will extend the company’s ability to manufacture creams, ointments, and semi-solids to support client’s clinical trial needs, including dealing with more complex formulations.
“This addition to our capabilities enables us to develop topical products on a larger scale and to cater for our clients’ supply needs from first-in-man studies up to and including Phase III, with a commercially replicable process in place,” said Claire Madden-Smith, SVP, at Juniper Pharma Services.
With an integrated electronic batch report system in place, the intuitive Becomix is designed to reduce operator input and automate the homogenization process. This is the latest major equipment initiative by the contract development and manufacturing organization, which recently announced an investment in its spray drying capabilities.
Source: Juniper Pharma Services